Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules.

Jessica L. Childs-Disney, Ewa Stepniak-Konieczna, Tuan Tran, Ilyas Yildirim, HaJeung Park, Catherine Z. Chen, Jason Hoskins, Noel Southall, Juan J. Marugan, Samarjit Patnaik, Wei Zheng, Chris P. Austin, George C Schatz, Krzysztof Sobczak, Charles A. Thornton, Matthew D. Disney

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

The ability to control pre-mRNA splicing with small molecules could facilitate the development of therapeutics or cell-based circuits that control gene function. Myotonic dystrophy type 1 is caused by the dysregulation of alternative pre-mRNA splicing due to sequestration of muscleblind-like 1 protein (MBNL1) by expanded, non-coding r(CUG) repeats (r(CUG)(exp)). Here we report two small molecules that induce or ameliorate alternative splicing dysregulation. A thiophene-containing small molecule (1) inhibits the interaction of MBNL1 with its natural pre-mRNA substrates. Compound (2), a substituted naphthyridine, binds r(CUG)(exp) and displaces MBNL1. Structural models show that 1 binds MBNL1 in the Zn-finger domain and that 2 interacts with UU loops in r(CUG)(exp). This study provides a structural framework for small molecules that target MBNL1 by mimicking r(CUG)(exp) and shows that targeting MBNL1 causes dysregulation of alternative splicing, suggesting that MBNL1 is thus not a suitable therapeutic target for the treatment of myotonic dystrophy type 1.

Original languageEnglish
Article number2044
JournalNature Communications
Volume4
Publication statusPublished - 2013

Fingerprint

splicing
Myotonic Dystrophy
RNA Precursors
induction
proteins
Defects
Molecules
defects
molecules
Proteins
Alternative Splicing
Naphthyridines
Thiophenes
Gene Regulatory Networks
Structural Models
thiophenes
genes
Fingers
Genes
Networks (circuits)

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Chemistry(all)
  • Physics and Astronomy(all)
  • Medicine(all)

Cite this

Childs-Disney, J. L., Stepniak-Konieczna, E., Tran, T., Yildirim, I., Park, H., Chen, C. Z., ... Disney, M. D. (2013). Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules. Nature Communications, 4, [2044].

Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules. / Childs-Disney, Jessica L.; Stepniak-Konieczna, Ewa; Tran, Tuan; Yildirim, Ilyas; Park, HaJeung; Chen, Catherine Z.; Hoskins, Jason; Southall, Noel; Marugan, Juan J.; Patnaik, Samarjit; Zheng, Wei; Austin, Chris P.; Schatz, George C; Sobczak, Krzysztof; Thornton, Charles A.; Disney, Matthew D.

In: Nature Communications, Vol. 4, 2044, 2013.

Research output: Contribution to journalArticle

Childs-Disney, JL, Stepniak-Konieczna, E, Tran, T, Yildirim, I, Park, H, Chen, CZ, Hoskins, J, Southall, N, Marugan, JJ, Patnaik, S, Zheng, W, Austin, CP, Schatz, GC, Sobczak, K, Thornton, CA & Disney, MD 2013, 'Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules.', Nature Communications, vol. 4, 2044.
Childs-Disney JL, Stepniak-Konieczna E, Tran T, Yildirim I, Park H, Chen CZ et al. Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules. Nature Communications. 2013;4. 2044.
Childs-Disney, Jessica L. ; Stepniak-Konieczna, Ewa ; Tran, Tuan ; Yildirim, Ilyas ; Park, HaJeung ; Chen, Catherine Z. ; Hoskins, Jason ; Southall, Noel ; Marugan, Juan J. ; Patnaik, Samarjit ; Zheng, Wei ; Austin, Chris P. ; Schatz, George C ; Sobczak, Krzysztof ; Thornton, Charles A. ; Disney, Matthew D. / Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules. In: Nature Communications. 2013 ; Vol. 4.
@article{3bb0748c482742e4844066525dcebc4c,
title = "Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules.",
abstract = "The ability to control pre-mRNA splicing with small molecules could facilitate the development of therapeutics or cell-based circuits that control gene function. Myotonic dystrophy type 1 is caused by the dysregulation of alternative pre-mRNA splicing due to sequestration of muscleblind-like 1 protein (MBNL1) by expanded, non-coding r(CUG) repeats (r(CUG)(exp)). Here we report two small molecules that induce or ameliorate alternative splicing dysregulation. A thiophene-containing small molecule (1) inhibits the interaction of MBNL1 with its natural pre-mRNA substrates. Compound (2), a substituted naphthyridine, binds r(CUG)(exp) and displaces MBNL1. Structural models show that 1 binds MBNL1 in the Zn-finger domain and that 2 interacts with UU loops in r(CUG)(exp). This study provides a structural framework for small molecules that target MBNL1 by mimicking r(CUG)(exp) and shows that targeting MBNL1 causes dysregulation of alternative splicing, suggesting that MBNL1 is thus not a suitable therapeutic target for the treatment of myotonic dystrophy type 1.",
author = "Childs-Disney, {Jessica L.} and Ewa Stepniak-Konieczna and Tuan Tran and Ilyas Yildirim and HaJeung Park and Chen, {Catherine Z.} and Jason Hoskins and Noel Southall and Marugan, {Juan J.} and Samarjit Patnaik and Wei Zheng and Austin, {Chris P.} and Schatz, {George C} and Krzysztof Sobczak and Thornton, {Charles A.} and Disney, {Matthew D.}",
year = "2013",
language = "English",
volume = "4",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules.

AU - Childs-Disney, Jessica L.

AU - Stepniak-Konieczna, Ewa

AU - Tran, Tuan

AU - Yildirim, Ilyas

AU - Park, HaJeung

AU - Chen, Catherine Z.

AU - Hoskins, Jason

AU - Southall, Noel

AU - Marugan, Juan J.

AU - Patnaik, Samarjit

AU - Zheng, Wei

AU - Austin, Chris P.

AU - Schatz, George C

AU - Sobczak, Krzysztof

AU - Thornton, Charles A.

AU - Disney, Matthew D.

PY - 2013

Y1 - 2013

N2 - The ability to control pre-mRNA splicing with small molecules could facilitate the development of therapeutics or cell-based circuits that control gene function. Myotonic dystrophy type 1 is caused by the dysregulation of alternative pre-mRNA splicing due to sequestration of muscleblind-like 1 protein (MBNL1) by expanded, non-coding r(CUG) repeats (r(CUG)(exp)). Here we report two small molecules that induce or ameliorate alternative splicing dysregulation. A thiophene-containing small molecule (1) inhibits the interaction of MBNL1 with its natural pre-mRNA substrates. Compound (2), a substituted naphthyridine, binds r(CUG)(exp) and displaces MBNL1. Structural models show that 1 binds MBNL1 in the Zn-finger domain and that 2 interacts with UU loops in r(CUG)(exp). This study provides a structural framework for small molecules that target MBNL1 by mimicking r(CUG)(exp) and shows that targeting MBNL1 causes dysregulation of alternative splicing, suggesting that MBNL1 is thus not a suitable therapeutic target for the treatment of myotonic dystrophy type 1.

AB - The ability to control pre-mRNA splicing with small molecules could facilitate the development of therapeutics or cell-based circuits that control gene function. Myotonic dystrophy type 1 is caused by the dysregulation of alternative pre-mRNA splicing due to sequestration of muscleblind-like 1 protein (MBNL1) by expanded, non-coding r(CUG) repeats (r(CUG)(exp)). Here we report two small molecules that induce or ameliorate alternative splicing dysregulation. A thiophene-containing small molecule (1) inhibits the interaction of MBNL1 with its natural pre-mRNA substrates. Compound (2), a substituted naphthyridine, binds r(CUG)(exp) and displaces MBNL1. Structural models show that 1 binds MBNL1 in the Zn-finger domain and that 2 interacts with UU loops in r(CUG)(exp). This study provides a structural framework for small molecules that target MBNL1 by mimicking r(CUG)(exp) and shows that targeting MBNL1 causes dysregulation of alternative splicing, suggesting that MBNL1 is thus not a suitable therapeutic target for the treatment of myotonic dystrophy type 1.

UR - http://www.scopus.com/inward/record.url?scp=84889102738&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889102738&partnerID=8YFLogxK

M3 - Article

VL - 4

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 2044

ER -